Bajaj Healthcare Limited delivered strong financial performance in Q3FY26, with the Board of Directors approving quarterly results and key leadership reappointments during their meeting held on January 16, 2026.

Strong Revenue Growth Drives Q3FY26 Performance

The pharmaceutical company demonstrated robust operational performance during the quarter ended December 31, 2025. Revenue from operations surged significantly compared to the previous year, reflecting the company's strengthened market position in the pharmaceuticals sector.

Nine-Month Performance Shows Consistent Growth

For the nine months ended December 31, 2025, Bajaj Healthcare maintained its growth trajectory across key financial parameters. The company's continuing operations demonstrated sustained profitability and operational efficiency.

Board Approves Key Leadership Reappointments

The Board of Directors approved the reappointment of four executive directors for three-year terms, demonstrating continuity in leadership. The reappointments are subject to shareholder approval through postal ballot.

Operational Highlights and Cost Management

The company's operational efficiency improved during Q3FY26, with total expenses rising to ₹14,362.52 crores from ₹11,351.30 crores in Q3FY25. Key expense components included cost of materials consumed at ₹6,940.90 crores and employee benefits expense of ₹1,558.66 crores. Finance costs decreased to ₹588.35 crores compared to ₹550.85 crores in the previous year quarter.

Discontinued Operations and Strategic Developments

The company reported a loss of ₹42.71 crores from discontinued operations in Q3FY26, compared to a loss of ₹324.44 crores in Q3FY25. This improvement reflects the company's strategic focus on core pharmaceutical operations. Additionally, Bajaj Healthcare acquired Genrx Pharmaceuticals Private Limited in April 2025 for ₹1,085 lakhs, with NCLT approval pending as of December 31, 2025.

Bajaj healthcare has announced the appointment of Mr. Umeshkumar Laxmidas Bhavsar as Additional Director in the Non-Executive Independent Director category. The appointment, effective January 13, 2026, was approved through a Board resolution passed by circulation based on the recommendation of the Nomination & Remuneration Committee.

Appointment Details

The key parameters of Mr. Bhavsar's appointment are outlined below:

Professional Background

Mr. Umeshkumar Laxmidas Bhavsar brings extensive professional experience to the Board. As a qualified Chartered Accountant, he has accumulated over 35 years of experience across multiple sectors including real estate, financial services, retail, manufacturing, and consulting. His expertise encompasses strategic financial planning and corporate finance management, supported by deep domain knowledge and technical proficiency.

Career Highlights

Mr. Bhavsar's professional journey includes significant tenure with Ajmera Realty & Infra India Limited, where he served for more than 15 years in financial leadership roles. During this period, he played a crucial role in strategic decision-making processes for the organization. Currently, he serves as a Designated Partner at RUHN Global Advisory LLP, Mumbai, a firm that specializes in providing corporate and business strategic advisory services.

Regulatory Compliance

The appointment adheres to all regulatory requirements under the Companies Act, 2013, and SEBI regulations. Mr. Bhavsar has confirmed his compliance with the following criteria:

• Meets the criteria of 'Independence' under Section 149 of the Companies Act, 2013
• Satisfies requirements under Regulation 16 of SEBI Listing Regulations
• Has not been debarred from holding directorship by SEBI or other authorities
• Is not related to any existing Directors of the Company

The appointment follows the disclosure requirements under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring full transparency and regulatory compliance for the pharmaceutical company's governance structure.